Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Poly-ICLC (Hiltonol) in Healthy COVID-19 Vaccinated Adults
NCT04672291Phase 1Completed
- Sponsor
- Oncovir, Inc.
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of poly iclc in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Oncovir, Inc. Primary endpoint: Safety and tolerability of nasally administered Poly-ICLC (Hiltonol®) in healthy adults at 91 days. Started Jul 2021; status: completed.
02
Drugs
poly iclc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04672291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672291.